Logo image of 1EXAS.MI

EXACT SCIENCES CORP (1EXAS.MI) Stock Fundamental Analysis

Europe - BIT:1EXAS - US30063P1057 - Common Stock

45.625 EUR
+7.13 (+18.51%)
Last: 9/15/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to 1EXAS. 1EXAS was compared to 77 industry peers in the Biotechnology industry. While 1EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, 1EXAS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

1EXAS had negative earnings in the past year.
In the past year 1EXAS had a positive cash flow from operations.
1EXAS had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: 1EXAS reported negative operating cash flow in multiple years.
1EXAS.MI Yearly Net Income VS EBIT VS OCF VS FCF1EXAS.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

1EXAS has a Return On Assets of -17.34%. This is comparable to the rest of the industry: 1EXAS outperforms 58.44% of its industry peers.
1EXAS's Return On Equity of -40.71% is in line compared to the rest of the industry. 1EXAS outperforms 58.44% of its industry peers.
Industry RankSector Rank
ROA -17.34%
ROE -40.71%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
1EXAS.MI Yearly ROA, ROE, ROIC1EXAS.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

1EXAS has a Gross Margin of 68.19%. This is in the better half of the industry: 1EXAS outperforms 61.04% of its industry peers.
1EXAS's Gross Margin has declined in the last couple of years.
1EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
1EXAS.MI Yearly Profit, Operating, Gross Margins1EXAS.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

1EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1EXAS has been increased compared to 1 year ago.
Compared to 5 years ago, 1EXAS has more shares outstanding
Compared to 1 year ago, 1EXAS has a worse debt to assets ratio.
1EXAS.MI Yearly Shares Outstanding1EXAS.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
1EXAS.MI Yearly Total Debt VS Total Assets1EXAS.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.34, we must say that 1EXAS is in the distress zone and has some risk of bankruptcy.
1EXAS has a Altman-Z score of 1.34. This is comparable to the rest of the industry: 1EXAS outperforms 58.44% of its industry peers.
1EXAS has a debt to FCF ratio of 18.77. This is a negative value and a sign of low solvency as 1EXAS would need 18.77 years to pay back of all of its debts.
1EXAS has a Debt to FCF ratio of 18.77. This is in the better half of the industry: 1EXAS outperforms 76.62% of its industry peers.
1EXAS has a Debt/Equity ratio of 0.94. This is a neutral value indicating 1EXAS is somewhat dependend on debt financing.
1EXAS has a Debt to Equity ratio of 0.94. This is comparable to the rest of the industry: 1EXAS outperforms 40.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF 18.77
Altman-Z 1.34
ROIC/WACCN/A
WACC8.82%
1EXAS.MI Yearly LT Debt VS Equity VS FCF1EXAS.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

1EXAS has a Current Ratio of 2.89. This indicates that 1EXAS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.89, 1EXAS is doing good in the industry, outperforming 62.34% of the companies in the same industry.
1EXAS has a Quick Ratio of 2.56. This indicates that 1EXAS is financially healthy and has no problem in meeting its short term obligations.
1EXAS has a better Quick ratio (2.56) than 61.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.56
1EXAS.MI Yearly Current Assets VS Current Liabilites1EXAS.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for 1EXAS have decreased strongly by -465.63% in the last year.
The Revenue has grown by 12.56% in the past year. This is quite good.
1EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.78% yearly.
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%

3.2 Future

The Earnings Per Share is expected to grow by 20.32% on average over the next years. This is a very strong growth
1EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.08% yearly.
EPS Next Y89.28%
EPS Next 2Y43.73%
EPS Next 3Y30.79%
EPS Next 5Y20.32%
Revenue Next Year14.88%
Revenue Next 2Y13.47%
Revenue Next 3Y12.95%
Revenue Next 5Y10.08%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1EXAS.MI Yearly Revenue VS Estimates1EXAS.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
1EXAS.MI Yearly EPS VS Estimates1EXAS.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

1EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 145.86, the valuation of 1EXAS can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1EXAS indicates a somewhat cheap valuation: 1EXAS is cheaper than 74.03% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.89, 1EXAS is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 145.86
1EXAS.MI Price Earnings VS Forward Price Earnings1EXAS.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1EXAS indicates a somewhat cheap valuation: 1EXAS is cheaper than 70.13% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1EXAS is valued a bit cheaper than 79.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 81.37
EV/EBITDA 171.82
1EXAS.MI Per share data1EXAS.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

1EXAS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
1EXAS's earnings are expected to grow with 30.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.73%
EPS Next 3Y30.79%

More info and screens

0

5. Dividend

5.1 Amount

1EXAS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXACT SCIENCES CORP

BIT:1EXAS (9/15/2025, 7:00:00 PM)

45.625

+7.13 (+18.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners98.76%
Inst Owner ChangeN/A
Ins Owners0.87%
Ins Owner ChangeN/A
Market Cap8.64B
Analysts85
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.73%
Min EPS beat(2)-39.07%
Max EPS beat(2)94.53%
EPS beat(4)2
Avg EPS beat(4)-333.88%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)5
Avg EPS beat(8)-143.38%
EPS beat(12)9
Avg EPS beat(12)-87.39%
EPS beat(16)11
Avg EPS beat(16)-65.6%
Revenue beat(2)2
Avg Revenue beat(2)1.64%
Min Revenue beat(2)0.62%
Max Revenue beat(2)2.65%
Revenue beat(4)2
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)2.65%
Revenue beat(8)2
Avg Revenue beat(8)-0.26%
Revenue beat(12)6
Avg Revenue beat(12)1.07%
Revenue beat(16)10
Avg Revenue beat(16)1.66%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 145.86
P/S 3.45
P/FCF 81.37
P/OCF 33.18
P/B 4.11
P/tB N/A
EV/EBITDA 171.82
EPS(TTM)-4.63
EYN/A
EPS(NY)0.31
Fwd EY0.69%
FCF(TTM)0.56
FCFY1.23%
OCF(TTM)1.38
OCFY3.01%
SpS13.23
BVpS11.11
TBVpS-3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.34%
ROE -40.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.19%
FCFM 4.24%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF 18.77
Debt/EBITDA 35.11
Cap/Depr 83.3%
Cap/Sales 6.16%
Interest Coverage N/A
Cash Conversion 459.82%
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.56
Altman-Z 1.34
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-465.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.89%
EPS Next Y89.28%
EPS Next 2Y43.73%
EPS Next 3Y30.79%
EPS Next 5Y20.32%
Revenue 1Y (TTM)12.56%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%15.99%
Revenue Next Year14.88%
Revenue Next 2Y13.47%
Revenue Next 3Y12.95%
Revenue Next 5Y10.08%
EBIT growth 1Y16.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year321.21%
EBIT Next 3Y82.67%
EBIT Next 5Y52.64%
FCF growth 1Y214.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y316.93%
OCF growth 3YN/A
OCF growth 5YN/A